Notch Therapeutics closes Vancouver lab, will focus on Toronto and Seattle offices

“Our goal is to build on core capabilities in Toronto and Seattle as we continue to develop our cell therapy pipeline. Notch has been making steady progress towards developing best-in-class iPSC-derived T cells, but we are making changes to sharpen our focus and ensure we remain operationally efficient during these externally challenging and turbulent times,” the company said in a statement.